Table 1.
Description of the immunized adults who provided blood samples
| Subject no. | Age, y | Sex | MenB vaccine* | Schedule | Interval since last dose, mo | MenA, C, Y, W vaccine† | Interval since last dose, mo |
|---|---|---|---|---|---|---|---|
| 001 | 50 | M | MenB-FHbp | 0, 1, 6 mo | 11-12 | MCV4-DT | 60 |
| 002 | 60 | M | MenB-FHbp | 0, 1, 6 mo | 11 | MCV4-DT (also MPSV4) | 120 |
| 003 | 28 | M | MenB-FHbp | 0, 1, 6 mo | 8 | MCV4-DT | 96 |
| 004 | 65 | F | MenB-FHbp | 0, 1, 6 mo | 9 | MCV4-DT (also MPSV4) | 24 |
| 005 | 33 | F | MenB-FHbp | 0, 1, 6 mo | 6 | MCV4-DT | 120 |
| 006 | 30 | F | MenB-FHbp | 0, 1, 6 mo | 11 | MCV4-DT | 132 |
| 007 | 23 | F | MenB-4C | 0, 1 mo, 1 y | 9 | MCV4-DT | 11 |
| 008 | 24 | F | MenB-4C | 0, 1 mo, 1 y | 6 | MCV4-DT | 11-12 |
| 009 | 35 | M | MenB-4C | 0, 1 mo | 6-8 | MCV4-DT | 8 |
| 010 | 25 | M | MenB-4C | 0, 1 mo, 1 y | 3-4 | MCV4-DT | 24 |
| 011 | 28 | F | MenB-4C | 0, 1 mo | 5-6 | MCV4-CRM | 12-13 |
| 012 | 41 | F | MenB-4C | 0, 1 mo | 2 | MCV4-DT | 60 |
All subjects were microbiologists or health care workers who had been immunized as part of previous immunogenicity studies,21,22 or at Employee Health at UCSF Benioff Children’s Hospital Oakland because of occupational exposure to N meningitidis.
*
MenB-FHbp (Trumbemba; Pfizer Vaccines); MenB-4C (Bexsero; GSK).
†
MCV4-DT (Menactra; Sanofi); MPSV4 (Menomune; Sanofi); MCV4-CRM (Menveo; GSK).